Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 757-768

  Paulitschke, Verena ^a   Berger, Walter ^b   Paulitschke, Philipp ^c   Hofstätter, Elisabeth ^a   Knapp, Bernhard ^d   Dingelmaier Hovorka, Ruth ^a   Födinger, Dagmar ^a   Jäger, Walter ^e   Szekeres, Thomas ^f   Meshcheryakova, Anastasia ^g   Bileck, Andrea ^e   Pirker, Christine ^b   Pehamberger, Hubert ^a   Gerner, Christopher ^e   Kunstfeld, Rainer ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF VIENNA   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',4,4',5,5' HEXAHYDROXYSTILBENE; ALPHA INTEGRIN; ALPHA5 INTEGRIN; B RAF KINASE; BETA INTEGRIN; CALCIUM ION; CYCLOOXYGENASE 2 INHIBITOR; DESMOPLAKIN; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; RESVERATROL; UNCLASSIFIED DRUG; UVOMORULIN; VEMURAFENIB; VIMENTIN; INDOLE DERIVATIVE; PROTEOME; SULFONAMIDE;

A375 CELL LINE; ANALYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BINDING; CANCER CELL LINE; CANCER RESISTANCE; CANCER THERAPY; CELL ADHESION; CELL ADHESION ASSAY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; ELECTRON MICROSCOPY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE; GEL ELECTROPHORESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; M24MET CELL LINE; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SHOTGUN ANALYSIS; SIGNAL TRANSDUCTION; STAINING; VM 1 CELL LINE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; PROCEDURES; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925160282     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0701     Document Type: Article

References (49)

1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007;82:490-513.
2. Bhatia S, Thompson JA. Systemic therapyformetastatic melanomain2012: dawn of a new era. J Natl Compr Canc Netw 2012;10:403-12.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumabinpatients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364:2507-16.
5. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistanceto RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
6. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012;24:150-4.
7. Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, et al. Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J Proteome Res 2013;12:3264-76.
8. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregula-tion. Nature 2010;468:973-7.
9. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-74.
10. Paulitschke V, Gruber S, Hofstatter E, Haudek-Prinz V, Klepeisz P, Schicher N, et al. Proteome analysisidentified thePPARgammaligand15d-PGJ2 asa novel drug inhibiting melanoma progression and interfering with tumorstroma interaction. PLoS ONE 2012;7:e46103.
11. Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Korner W, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sor-afenib in vitro and in vivo. Eur J Cancer 2013;49:3366-75.
12. Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lotsch D, Heffeter P, et al. Aggressivenessofhuman melanoma xenograft modelsispromoted by aneuploidy-driven gene expression deregulation. Oncotarget 2012;3: 399-413.
13. Paulitschke V, Schicher N, Szekeres T, Jager W, Elbling L, Riemer AB, et al. 3, 3′, 4, 4′, 5, 5′-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. J Invest Dermatol 2010;130:1668-79.
14. Slany A, Haudek-Prinz V, Meshcheryakova A, Bileck A, Lamm W, Zielinski C, et al. Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res 2014;13:844-54.
15. Bray DF, Bagu J, Koegler P. Comparison of hexamethyldisilazane (HMDS), Peldri II, and critical-point drying methods for scanning electron microscopy of biological specimens. Microsc Res Tech 1993;26:489-95.
16. Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, et al. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol 2005;124:1293-9.
17. Slany A, Haudek-Prinz V, Zwickl H, Stattner S, Grasl-Kraupp B, Gerner C. Myofibroblasts are important contributors to human hepatocellular carcinoma: evidence for tumor promotion by proteome profiling. Electro-phoresis 2013;34:3315-25.
18. Rabilloud T, Strub JM, Luche S, van Dorsselaer A, Lunardi J. A comparison between Sypro Ruby and ruthenium II tris (bathophenanthroline disulfo-nate) as fluorescent stains for protein detection in gels. Proteomics 2001;1:699-704.
19. Bileck A, Kreutz D, Muqaku B, Slany A, Gerner C. Comprehensive assessment of proteins regulated by dexamethasone reveals novel effects in primary human peripheral blood mononuclear cells. J Proteome Res 2014;13:5989-6000.
20. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367-72.
21. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics 2012;13 Suppl 16:S12.
22. Geiger T, Cox J, Mann M. Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet 2010;6:e1001090.
23. Slany A, Haudek VJ, Gundacker NC, Griss J, Mohr T, Wimmer H, et al. Introducing a new parameter for quality control of proteome profiles: consideration of commonly expressed proteins. Electrophoresis 2009;30: 1306-28.
24. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
25. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
26. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012;72:4883-9.
27. Korabiowska M, Quentin T, Schlott T, Bauer H, Kunze E. Down-regulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression. World J Urol 2004; 22:431-40.
28. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phos-phorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34.
29. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-7.
30. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy ofaRAFinhibitor needs broad targetblockadeinBRAF-mutantmelanoma. Nature 2010;467:596-9.
31. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance toRAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.
32. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
33. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
34. Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget 2011;2:329-35.
35. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013;23:811-25.
36. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014;124:1406-17.
37. Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene 2006;25:7117-30.
38. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
39. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53in mice leadstometastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
40. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
41. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012;69:3429-56.
42. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E (2) induces transcriptional repressors ZEB1 and snailinnon-small cell lung cancer. Cancer Res 2006;66:5338-45.
43. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004;18:1131-43.
44. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 2008;29: 2227-35.
45. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30: 377-86.
46. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.
47. Choi Y, Deane CM. FREAD revisited: Accurate loop structure prediction using a database search algorithm. Proteins 2010;78:1431-40.
48. Kelm S, Shi J, Deane CM. MEDELLER: homology-based coordinate generation for membrane proteins. Bioinformatics 2010;26: 2833-40.
49. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005;4: 1265-72.